Ozempic is FDA-approved to treat type 2 diabetes in adults. It is not approved for weight loss, though it is widely prescribed off-label for that purpose. The drug has three specific approved uses, all tied to type 2 diabetes: improving blood sugar control, reducing cardiovascular risk in people with heart disease, and protecting kidney function in people with chronic kidney disease.
The Three FDA-Approved Uses
Ozempic’s core approval is for blood sugar management in adults with type 2 diabetes, used alongside diet and exercise. Across clinical trials in the SUSTAIN program, patients saw their A1C levels drop by 0.6 to 1.6 percentage points compared to other treatments, a meaningful improvement for most people with diabetes.
The second approved use targets heart health. Adults with type 2 diabetes who also have established cardiovascular disease can take Ozempic to lower their risk of heart attack, stroke, or cardiovascular death. The third and most recent approval covers kidney protection: reducing the risk of kidney failure and declining kidney function in adults with both type 2 diabetes and chronic kidney disease. In the FLOW trial, published in the New England Journal of Medicine, patients on semaglutide had a 24% lower risk of major kidney events compared to placebo, and their annual loss of kidney function slowed significantly.
All three indications require a type 2 diabetes diagnosis. Ozempic is not approved for type 1 diabetes.
How Ozempic Works in Your Body
Ozempic contains semaglutide, which mimics a natural gut hormone called GLP-1. Your body normally releases this hormone after eating, and it does several things at once. It signals your pancreas to release insulin, which pulls sugar out of your bloodstream and into your cells. It also blocks glucagon, a hormone that raises blood sugar, preventing extra glucose from entering your blood when it’s not needed.
The third effect is the one that gets the most attention: GLP-1 acts on areas of the brain that regulate hunger and fullness. People taking Ozempic typically feel satisfied sooner during meals and stay full longer afterward. This appetite suppression is what drives the significant weight loss many users experience, even though the drug was designed for blood sugar control.
Why Ozempic Gets Prescribed for Weight Loss
Despite not being approved for weight management, Ozempic is frequently prescribed off-label for weight loss. Nearly 2% of Americans were prescribed semaglutide medications in 2023, a 40-fold increase over the previous five years, and a large share of that growth comes from people without diabetes seeking weight loss.
The clinical rationale is straightforward. In weight loss studies, almost 80% of patients on semaglutide lost at least 5% of their body weight, and 42% lost at least 15%. Those are results that rival or exceed most other available treatments. Doctors prescribe Ozempic rather than Wegovy (the semaglutide brand approved for weight loss) for a few practical reasons: availability, insurance coverage patterns, and familiarity with the product.
This off-label surge has created real problems. Shortages have made it harder for people with diabetes to access the medication they depend on for blood sugar control. Many insurers refuse to cover GLP-1 drugs for weight loss, leaving patients paying $1,300 or more per month out of pocket. Some insurers have gone further, threatening to report physicians to state licensing boards for off-label prescribing.
Ozempic vs. Wegovy
Ozempic and Wegovy contain the same active ingredient, semaglutide, but they are legally distinct products with different approved uses. Wegovy is approved for weight management in adults and children 12 and older, for a type of fatty liver disease called MASH, and for cardiovascular risk reduction in adults with obesity or overweight and heart disease. Ozempic’s approvals all require a type 2 diabetes diagnosis.
The dosing also differs. Ozempic maxes out at 2 mg per week, while Wegovy goes up to 2.4 mg. Both are available as weekly injections and daily pills, though the injection pens work differently: Wegovy uses single-use pens, while Ozempic pens are designed for multiple doses.
What the Dosing Schedule Looks Like
Ozempic starts at a low dose and builds gradually to reduce side effects, especially nausea. You begin with 0.25 mg once a week for four weeks. This starting dose is purely to let your body adjust and does not provide meaningful blood sugar control on its own. After four weeks, the dose increases to 0.5 mg weekly. If blood sugar levels still need improvement after at least another four weeks, your doctor may raise it to 1 mg weekly. The maximum recommended dose is 2 mg once weekly.
The injection goes under the skin of the abdomen, thigh, or upper arm. You pick a day of the week and stick with it, though the exact time of day doesn’t matter.
Who Should Not Take Ozempic
Semaglutide carries a boxed warning, the FDA’s strongest safety alert, about the risk of thyroid C-cell tumors. Ozempic is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2. It’s also contraindicated if you’ve had a serious allergic reaction to semaglutide.
Beyond the formal contraindications, you should avoid Ozempic if you’re pregnant or have severe gastroparesis, a condition where the stomach can’t empty properly. Since semaglutide slows gastric emptying as part of how it works, it can worsen this condition significantly.